How Long Has Semaglutide Been Around? A Full Timeline of Development & Impact

The Early Days: Where GLP-1 Research Began

Semaglutide’s development is rooted in GLP-1 research from the 1970s, when scientists like Jens Juul Holst began exploring the hormone’s potential role in supporting insulin secretion and regulating appetite. By the 1980s, early studies suggested that GLP-1 analogues might offer therapeutic benefits for managing type 2 diabetes.

‍

Development of Semaglutide

Following the regulatory approval and clinical adoption of liraglutide in the late 1990s, Novo Nordisk began research aimed at developing a longer-acting GLP-1 receptor agonist:

• Early 2000s: Research into semaglutide began, focusing on chemical modifications to extend its half-life.
• 2008: Semaglutide entered Phase II clinical trials.
• 2012: Key patents related to the molecule’s design were filed.
• 2015: The SUSTAIN clinical trial program was launched to evaluate semaglutide’s safety and efficacy.

When Was Semaglutide Approved?

‍

‍

Licensed healthcare providers on the Eden platform may discuss GLP-1–based treatment options that are appropriate for each individual's needs.

‍

Semaglutide’s Role in Weight Loss

In the STEP clinical trials, participants with obesity or overweight receiving semaglutide alongside lifestyle interventions experienced average weight reductions of 14.9% to 17.4% over 68 weeks. These studies, published in peer-reviewed journals, were conducted in controlled environments with medical oversight. Individual outcomes may vary, and this data should not be interpreted as a guaranteed result outside of clinical settings. Licensed providers can evaluate whether GLP-1–based treatments are appropriate based on your individual health profile.

‍

Real-World Effectiveness

Some observational reports outside of controlled trials suggest that individuals prescribed semaglutide under licensed medical supervision may experience weight-related changes over several months. Reported weight changes have varied widely, and outcomes depend heavily on adherence, lifestyle factors, and individual response. These findings should not be used as a substitute for clinical trial data, and licensed providers can help patients understand what to expect based on their own health history.

‍

Semaglutide vs Other Medications

‍

‍

Licensed healthcare providers on the Eden platform may help determine whether GLP-1–based treatments are appropriate for your individual needs.

‍

Broader Health Benefits Under Study

Researchers are currently investigating whether GLP-1 receptor agonists may influence areas such as cardiovascular health, kidney function, liver metabolism, and sleep-related conditions. While some studies have explored these topics, these are not FDA-approved uses, and evidence remains limited or preliminary. Patients should speak with a licensed healthcare provider to understand what is supported by current research and what is still under evaluation.

‍

How Long Does It Take to Work?

In clinical studies, some participants reported appetite-related changes within the first 1–2 weeks, with weight-related changes sometimes observed between weeks 4 and 6. Results varied, and long-term success often involved lifestyle changes and regular medical supervision.

Eden connects patients with licensed healthcare providers who can help assess whether GLP-1–based treatments may be appropriate for their goals.

‍

Safety and Side Effects

In clinical trials, semaglutide was generally well-tolerated, though some participants experienced gastrointestinal symptoms such as nausea, constipation, or diarrhea. These effects were usually mild and tended to improve over time. More serious risks, such as pancreatitis or gallbladder issues, have also been reported and should be discussed with a licensed healthcare provider before starting any treatment.

‍

Final Thoughts

Semaglutide’s development—rooted in decades of GLP-1 hormone research—represents a significant milestone in how clinicians approach certain chronic conditions like type 2 diabetes and obesity. It has shown promising results in controlled studies as an FDA-approved treatment under specific brand names. 

Eden connects patients with licensed healthcare providers who can evaluate whether GLP–1–based therapies may be appropriate based on their individual needs and goals.

‍

‍